New drug combo aims to fight bladder cancer when standard treatment fails
NCT ID NCT06388720
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk bladder cancer that did not respond to BCG therapy. The study will enroll 82 participants to see if this sequential treatment can prevent cancer from coming back or getting worse. Researchers will also monitor safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mitomycin-C and gemcitabine
What this could lead to
If successful, this could offer a new treatment option for people with high-risk bladder cancer that hasn't responded to standard therapy, potentially delaying recurrence or progression.
What could go wrong
This is a small, early-phase (phase 2) trial with only 82 participants, so results may not apply to everyone. The treatment may not work better than existing options, and side effects from the bladder instillations are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center
RECRUITINGGoyang-si, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact